ARTICLE | Product Development
New variant-hardy AbCellera-Lilly mAb shows utility of viral genomics surveillance
The antiviral mAb enters the clinic with promising data on variant neutralization and the rarity of resistant mutations
May 5, 2021 1:25 AM UTC
As Lilly and AbCellera bring their next-generation COVID mAb to the clinic, their preclinical data highlights the critical role of sample access and global viral surveillance data in variant-proofing therapies.
Eli Lilly and Co. (NYSE:LLY) and AbCellera Biologics Inc. (NASDAQ:ABCL) announced Tuesday that LY-CoV1404 (LY3853113), the second mAb from their collaboration, began testing in mild-to-moderate COVID-19 patients via Lilly’s ongoing Phase II BLAZE-4 trial. ...